Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
O00451

UPID:
GFRA2_HUMAN

ALTERNATIVE NAMES:
GDNF receptor beta; Neurturin receptor alpha; RET ligand 2; TGF-beta-related neurotrophic factor receptor 2

ALTERNATIVE UPACC:
O00451; E9PD47; O15316; O15328; Q58J92; Q6GTR9; Q7Z5C2

BACKGROUND:
The protein GDNF family receptor alpha-2, with alternative names such as RET ligand 2 and TGF-beta-related neurotrophic factor receptor 2, is integral to neurotrophic signaling. It serves as a receptor for neurturin, triggering the RET receptor's autophosphorylation and activation, and is capable of mediating GDNF signaling. This receptor's function in STAT3 phosphorylation underscores its importance in cellular signaling pathways.

THERAPEUTIC SIGNIFICANCE:
The exploration of GDNF family receptor alpha-2's functions offers promising avenues for developing novel therapeutic approaches. Given its pivotal role in neurotrophic signaling, targeting this receptor could lead to breakthroughs in treatments for neurodegenerative conditions and support the regeneration of nervous tissue.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.